- Argenx (NASDAQ:ARGX) is up 9% premarket on reporting data from its Phase 2 clinical trial of efgartigimod (ARGX-113) in immune thrombocytopenia (ITP) and the Phase 1 portion of its Phase 1/2 trial of cusatuzumab (ARGX-110) in acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS) during a workshop at ASH Annual Meeting and Exposition.
- Detailed Phase 2 ITP data show clear correlation between IgG reduction, platelet count increase and reduction of bleeding events.
- New cusatuzumab data in AML resulted in a 92% response rate with 10 of 12 patients showing a complete response (CR/CRi).
- The median duration on trial as of data cut-off was 8.1 months, ranging from 2 to 17.4 months, with 6 patients still on trial.
- Translational data demonstrated that cusatuzumab monotherapy and in combination with Celgene's Vidaza (azacitidine) reduced leukemic stem cells in the bone marrow of AML patients.
- #ASH18